Answers are grounded in this paper and cite their sources.
Introduction: Dupilumab reduces rates of asthma exacerbations and improves lung function in children (VOYAGE, NCT02948959) and adults and adolescents (QUEST, NCT02414854) with uncontrolled, moderate-to-severe asthma. Previous data have demonstrated that fractional exhaled nitric oxide (FeNO) is a valid prognostic biomarker, a predictor of response to dupilumab.
No takes yet. Share an insight, caveat, or question.
Busse et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: